<DOC>
	<DOCNO>NCT00424034</DOCNO>
	<brief_summary>To investigate safety , tolerability , pharmacokinetics effect food pharmacokinetics single oral administration GSK1325760A</brief_summary>
	<brief_title>A Study GSK1325760A Healthy Japanese Subjects</brief_title>
	<detailed_description>Phase1 study GSK1325760A - A double blind , single center , randomise , placebo-controlled , partially crossover , single dose study investigate safety , tolerability , pharmacokinetics assess effect food pharmacokinetics ascend oral dos GSK1325760A healthy Japanese male subject -</detailed_description>
	<criteria>They consider healthy investigator screen . Healthy subject define individual free clinically significant illness disease determine medical history , physical examination , clinical laboratory test , vital sign , 12lead ECG , immunology test urinary drug screening test . They Japanese male . Aged 20 64 year , inclusive . They body mass index ( weight/height2 ) screening range 18.5 &lt; 25.0 kg/m2 inclusive . Standard weight range 5585 kg inclusive . Blood pressure pulse rate screen within normal range ( systolic 90140 mmHg , diastolic 4090 mmHg , pulse rate 4090bpm ) . They follow clinical laboratory test Biochemistry ( AST ( GOT ) , ALT ( GPT ) , ALP , LDH gammaGTP : within normal range screening . Haematology ( RBC , Hb Ht ) upper limit normal range screen . Normal ECG screening ( QTc value &lt; 440msec ) . They give consent able abstain sexual intercourse use condom contraception screen poststudy screen . They capable give write informed consent , include compliance requirement restriction list consent form . They nonsmoker ( least 6 month ) . They able attend visit complete study . The subject clinically relevant abnormality medical examination , vital sign , clinical laboratory test medical history screen medical opinion investigator subject medical history consider eligible inclusion study investigator . The subject allergy drug idiosyncrasy . This exclude pollen allergy without current symptom . The subject participate clinical study postmarketing study investigational noninvestigational product device previous 4 month first dose . The subject concurrently participate another clinical study postmarketing study subject expose investigational noninvestigational product device . The subject positive syphilis , HBs antigen , HCV antibody , HIV antibody , HTLV1 antibody . The subject positive urine drug abuse test . The subject donate unit blood ( &gt; 400mL ) within previous 4 month ( &gt; 200mL ) within previous 1 month screening . The subject currently take regular ( course ) medication ( include prescribe drug , overthecounter medication herbal preparation ) . Medication permit study must discontinue 14 day prior dose . The subject history current condition drug abuse alcoholism accord ICD10 . The subject history regular alcohol consumption exceed 7 drinks/week ( 1 drink = 350mL beer ) within 6 month first dose .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>effect food pharmacokinetics</keyword>
</DOC>